相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome
Sara Ruiz-Pinto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
Josep Corominas et al.
CANCERS (2021)
Computational analyses prioritize and reveal the deleterious nsSNPs in human angiotensinogen gene
Achintya Mohan Goswami
COMPUTATIONAL BIOLOGY AND CHEMISTRY (2020)
Prognostic and Immunological Value of Angiotensin-Converting Enzyme 2 in Pan-Cancer
Huan Feng et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Fiamma Berner et al.
JAMA ONCOLOGY (2019)
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
Giorgia Marisi et al.
CANCERS (2019)
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib
Alvaro Diaz-Gonzalez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events
Jordi Rimola et al.
HEPATOLOGY (2018)
Balance and circumstance: The renin angiotensin system in wound healing and fibrosis
Rocco Bernasconi et al.
CELLULAR SIGNALLING (2018)
Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma
Alexander Perdomo-Pantoja et al.
PLOS ONE (2018)
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.
Jordi Bruix et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
Thomas Urup et al.
MOLECULAR ONCOLOGY (2016)
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
Andrea Casadei Gardini et al.
ONCOTARGET (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
The Adverse Effects of Sorafenib in Patients with Advanced Cancers
Ye Li et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients
Diana Moreno-Munoz et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2014)
Assessment of two missense polymorphisms (rs4762 and rs699) of the angiotensinogen gene and stroke
Hyun-Kyung Park et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2013)
Estimation of risk and interaction of single nucleotide polymorphisms at angiotensinogen locus causing susceptibility to essential hypertension: a case control study
Bh Charita et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2012)
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk
Georg B. Ehret et al.
NATURE (2011)
Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy
Michael Bader
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
The renin-angiotensin system and malignancy
Eleanor I. Ager et al.
CARCINOGENESIS (2008)
Influence of skin color in the development of erlotinib-induced rash: A report from the SERIES clinic
S. E. Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failure
Anna P. Pilbrow et al.
HYPERTENSION (2007)
Hand-foot and stump syndrome to sorafenib
Susan E. Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II
L Hunyady et al.
MOLECULAR ENDOCRINOLOGY (2006)
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert et al.
LANCET ONCOLOGY (2005)
Release of doxorubicin in sweat:: first step to induce the palmarplantar erythrodysesthesia syndrome?
U Jacobi et al.
ANNALS OF ONCOLOGY (2005)
Drug therapy - Drug metabolism and variability among patients in drug response
GR Wilkinson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Human skin:: source of and target organ for angiotensin II
UM Steckelings et al.
EXPERIMENTAL DERMATOLOGY (2004)
分享论文
